AP NEWS
ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by ...

December 17, 2020 GMT

CAMBRIDGE, United Kingdom, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™.   This is the first license under a multi-product development agreement between Inhibrx and Arecor.

INBRX-101 is a precisely engineered recombinant human Alpha-1 Antitrypsin Fc-fusion protein for the treatment of Alpha-1 antitrypsin deficiency (AATD).  AATD is an underdiagnosed inherited orphan genetic disease that can cause serious lung disease in adults and/or liver disease at any age. Arestat™ is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of therapeutic proteins and peptides.  This collaboration demonstrates the unique capability of the Arestat™ technology to deliver superior reformulations of complex fusion proteins in this case for treatment of an orphan disease.

ADVERTISEMENT

 Please click on or paste the following URL into your web browser to view the announcement in full:

http://www.rns-pdf.londonstockexchange.com/rns/8901I_1-2020-12-16.pdf

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact  rns@lseg.com  or visit  www.rns.com.